Wedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target to $113.00 (from $106.00), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE